과제정보
연구 과제 주관 기관 : Universiti Sains Malaysia, Ministry of Higher Education of Malaysia
참고문헌
- Agarwal S, Sharma MC, Jha P, et al (2013). Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol, 15, 718-26. https://doi.org/10.1093/neuonc/not015
- Ahmadi R, Stockhammer F, Becker N, et al (2012). No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol, 109, 15-22. https://doi.org/10.1007/s11060-012-0863-y
- Baldewpersad Tewarie NM, Burgers IA, Dawood Y, et al (2013). NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival. Med Hypotheses, 80, 728-31. https://doi.org/10.1016/j.mehy.2013.02.022
- Balss J, Meyer J, Mueller W, et al (2008). Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol, 116, 597-602. https://doi.org/10.1007/s00401-008-0455-2
- Bleeker FE, Lamba S, Leenstra S, et al (2009). IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat, 30, 7-11. https://doi.org/10.1002/humu.20937
- Chen JR, Yao Y, Xu HZ, et al (2016). Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore), 95, e2583. https://doi.org/10.1097/MD.0000000000002583
- Das BR, Tangri R, Ahmad F, et al (2013). Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. Asian Pac J Cancer Prev, 14, 7261-4. https://doi.org/10.7314/APJCP.2013.14.12.7261
- de Robles P, Fiest KM, Frolkis AD, et al (2015). The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol, 17, 776-83. https://doi.org/10.1093/neuonc/nou283
- Elsayed GM, Nassar HR, Zaher A, et al (2014). Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients. J Egypt Natl Canc Inst, 26, 43-9. https://doi.org/10.1016/j.jnci.2013.11.001
- Goh CH, Lu YY, Lau BL, et al (2014). Wong A. Brain and spinal tumour. Med J Malaysia, 69, 261-7.
- Guan L, Gao L, Wang L, et al (2013). The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients. PLoS One, 8, e83334. https://doi.org/10.1371/journal.pone.0083334
- Gupta R, Flanagan S, Li CC, et al (2013). Expanding the spectrum of IDH1 mutations in gliomas. Mod Pathol, 26, 619-25. https://doi.org/10.1038/modpathol.2012.210
- Ha SY, Kang SY, Do IG, et al (2013). Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol, 112, 439-48. https://doi.org/10.1007/s11060-013-1073-y
- Hartmann C, Meyer J, Balss J, et al (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol, 118, 469-74. https://doi.org/10.1007/s00401-009-0561-9
- Houillier C, Wang X, Kaloshi G, et al (2010). IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology, 75, 1560-6. https://doi.org/10.1212/WNL.0b013e3181f96282
- Ichimura K, Pearson DM, Kocialkowski S, et al (2009). IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol, 11, 341-7. https://doi.org/10.1215/15228517-2009-025
- Im AP, Sehgal AR, Carroll MP, et al (2014). DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia, 28, 1774-83. https://doi.org/10.1038/leu.2014.124
- Jha P, Suri V, Sharma V, et al (2011). IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol, 91, 385-93. https://doi.org/10.1016/j.yexmp.2011.04.017
- Jin J, Hu C, Yu M, et al (2014). Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS One, 9, e100206. https://doi.org/10.1371/journal.pone.0100206
- Kang MR, Kim MS, Oh JE, et al (2009). Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer, 125, 353-5. https://doi.org/10.1002/ijc.24379
- Li J, Zhang H, Wang L, et al (2015). Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing. Mol Med Rep, 12, 4376-81. https://doi.org/10.3892/mmr.2015.3987
- Li MY, Wang YY, Cai JQ, et al (2015). Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in clinical lowgrade gliomas. PLoS One, 10, e0130872. https://doi.org/10.1371/journal.pone.0130872
- Lim CC, Rampal S, Halimah Y (2008). Cancer incidence in Peninsular Malaysia, 2003-2005. Kuala Lumpur: National Cancer Registry; 2008.
- Lin J, Yao DM, Qian J, et al (2012). IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol, 91, 519-25. https://doi.org/10.1007/s00277-011-1352-7
- Meyer J, Pusch S, Balss J, et al (2010). PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol, 20, 298-300. https://doi.org/10.1111/j.1750-3639.2009.00327.x
- Molenaar RJ, Thota S, Nagata Y, et al (2015). Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia, 29, 2134-42. https://doi.org/10.1038/leu.2015.91
- Mondesir J, Willekens C, Touat M, et al (2016). IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med, 7, 171-80. https://doi.org/10.2147/JBM.S70716
- Mukasa A, Takayanagi S, Saito K, et al (2012). Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci, 103, 587-92. https://doi.org/10.1111/j.1349-7006.2011.02175.x
- Myung JK, Cho HJ, Park CK, et al (2012). IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep, 28, 1639-44. https://doi.org/10.3892/or.2012.1994
- Nobusawa S, Watanabe T, Kleihues P, et al (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res, 15, 6002-7. https://doi.org/10.1158/1078-0432.CCR-09-0715
- Ohno M, Narita Y, Miyakita Y, et al (2016). Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome. Jpn J Clin Oncol, 46, 31-9. https://doi.org/10.1093/jjco/hyv170
- Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. https://doi.org/10.1126/science.1164382
- Platt MY, Fathi AT, Borger DR, et al (2015). Detection of dual IDH1 and IDH2 mutations by targeted next-generation sequencing in acute myeloid leukemia and myelodysplastic syndromes. J Mol Diagn, 17, 661-8. https://doi.org/10.1016/j.jmoldx.2015.06.004
- Polivka J, Polivka J Jr, Rohan V, et al (2014). Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia. Biomed Res Int, 2014, 735659.
- Qi S, Yu L, Li H, et al (2014). Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett, 7, 1895-1902. https://doi.org/10.3892/ol.2014.2013
- Qi ST, Yu L, Lu YT, et al (2011). IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep, 26, 1479-85.
- Raveendran S, Sarojam S, Vijay S, et al (2015). Mutation analysis of IDH1/2 genes in unselected de novo acute myeloid leukaemia patients in India - identification of a Novel IDH2 mutation. Asian Pac J Cancer Prev, 16, 4095-101. https://doi.org/10.7314/APJCP.2015.16.9.4095
- Sanson M, Marie Y, Paris S, et al (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol, 27, 4150-4. https://doi.org/10.1200/JCO.2009.21.9832
- Siegel RL, Miller KD, Jemal A, (2016). Cancer statistics, 2016. CA Cancer J Clin, 66, 7-30. https://doi.org/10.3322/caac.21332
- SongTao Q, Lei Y, Si G, et al (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci, 103, 269-73. https://doi.org/10.1111/j.1349-7006.2011.02134.x
- Sonoda Y, Kumabe T, Nakamura T, et al (2009). Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci, 100, 1996-8. https://doi.org/10.1111/j.1349-7006.2009.01270.x
- Stupp R, Brada M, van den Bent MJ, et al (2014). High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 25, 93-101.
- Thon N, Eigenbrod S, Kreth S, et al (2012). IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer, 118, 452-60. https://doi.org/10.1002/cncr.26298
- Thota B, Shukla SK, Srividya MR, et al (2012). IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Am J Clin Pathol, 138, 177-84. https://doi.org/10.1309/AJCPZOIY3WY4KIKE
- Wang HY, Tang K, Liang TY, et al (2016). The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res, 35, 86. https://doi.org/10.1186/s13046-016-0362-7
- Watanabe T, Nobusawa S, Kleihues P, et al (2009). IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol, 174, 1149-53. https://doi.org/10.2353/ajpath.2009.080958
- Yan H, Parsons DW, Jin G, et al (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360, 765-73. https://doi.org/10.1056/NEJMoa0808710
- Yan W, Zhang W, You G, et al (2012). Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One, 7, e30339. https://doi.org/10.1371/journal.pone.0030339
- Yao Y, Chan AK, Qin ZY, et al (2013). Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival. PLoS One, 8, e67421. https://doi.org/10.1371/journal.pone.0067421
- Zhang CB, Bao ZS, Wang HJ, et al (2014). Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. J Cancer Res Clin Oncol, 140, 45-51. https://doi.org/10.1007/s00432-013-1519-9
- Zhou YX, Wang JX, Feng M, et al (2012). Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. J Mol Neurosci, 47, 442-7. https://doi.org/10.1007/s12031-011-9681-5
- Zou P, Xu H, Chen P, et al (2013). IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One, 8, e68782. https://doi.org/10.1371/journal.pone.0068782
- Zou Y, Zeng Y, Zhang DF, et al (2010). IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun, 402, 378-83. https://doi.org/10.1016/j.bbrc.2010.10.038